CO6150139A2 - Sal de tartrato de 1-[2- fluoruro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3 oxazol-5-il)-4h-1,2,4-triazol-3 il]tio}propil)-3-azabiciclo[3.1.0]-hexano y a sus solvatos, formulaciones farmaceuticas, procedimientos para su preparacion y su - Google Patents
Sal de tartrato de 1-[2- fluoruro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3 oxazol-5-il)-4h-1,2,4-triazol-3 il]tio}propil)-3-azabiciclo[3.1.0]-hexano y a sus solvatos, formulaciones farmaceuticas, procedimientos para su preparacion y suInfo
- Publication number
- CO6150139A2 CO6150139A2 CO09017330A CO09017330A CO6150139A2 CO 6150139 A2 CO6150139 A2 CO 6150139A2 CO 09017330 A CO09017330 A CO 09017330A CO 09017330 A CO09017330 A CO 09017330A CO 6150139 A2 CO6150139 A2 CO 6150139A2
- Authority
- CO
- Colombia
- Prior art keywords
- methyl
- oxazol
- triazol
- phenyl
- azabiciclo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
1.- Tartrato de 1-[2-fluoro-4-(trifluorometil)fenil]-3-(3{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4H-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3.1.0)-hexano o su solvato farmacéuticamente aceptable. 2.- Tartrato de (1S,5R)-1-[2-fluoro-4-(trifluorometil)fenil)-3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4H-1,2,4-triazol-3-il)tio}propil)-3-azabiciclo[3.1.0)-hexano o su solvato farmacéutícamente aceptable. 3.- Tartrato de (1S,5R)-1-[2-fluoro-4-(trlfluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4H-1,2,4-triazol-3-iI)tio}propil)-3-azabiciclo[3.1.0)-hexano (2R,3R) o su solvato farmacéuticamente aceptable. 4.- Un compuesto según la reivindicación 1, la reivindicación 2 o la reivindicación 3, en el que la relación de 1-[2-fluoro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4H-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo [3.1.0)-hexano o (1S,5R)-1-[2-fluoro-4-(trifluoro-metil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-il)-4H-1,2,4-triazol-3-il)tio}propil)-3-azabiciclo[3.1.0)-hexano a ácido tartárico (en moles) es 1:1. 5.- Un compuesto según cualquiera de las reivindicaciones 2-4, en el que la relación de (1S, 5R)-1-[2-fluoro-4-(trifluoro-metil)fenil)-3-(3-{(4-metil-5-(4-metil-1,3- oxazol-5-il)-4H-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3.1.0)-hexano a (2R,3R) ácido tartárico (en moles) es 1:1.6.- Un compuesto según cualquiera de las reivindicaciones 2-5, que es un hidrato. 7.- Un compuesto según cualquiera de las reivindicaciones 2-6, que es un sesquihidrato. 8.- Un compuesto según cualquiera de las reivindicaciones 2-7, en forma cristalina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2006/008314 WO2007022980A1 (en) | 2005-08-22 | 2006-08-21 | Use of azabicyclo hexane derivatives |
GBGB0616574.0A GB0616574D0 (en) | 2006-08-21 | 2006-08-21 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6150139A2 true CO6150139A2 (es) | 2010-04-20 |
Family
ID=37081324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09017330A CO6150139A2 (es) | 2006-08-21 | 2009-02-20 | Sal de tartrato de 1-[2- fluoruro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3 oxazol-5-il)-4h-1,2,4-triazol-3 il]tio}propil)-3-azabiciclo[3.1.0]-hexano y a sus solvatos, formulaciones farmaceuticas, procedimientos para su preparacion y su |
Country Status (22)
Country | Link |
---|---|
US (1) | US20080058398A1 (es) |
EP (1) | EP2054054A1 (es) |
JP (1) | JP5315244B2 (es) |
KR (1) | KR101495362B1 (es) |
CN (1) | CN101528221B (es) |
AR (1) | AR062471A1 (es) |
AU (1) | AU2007287527B2 (es) |
BR (1) | BRPI0716454A2 (es) |
CA (1) | CA2661437A1 (es) |
CL (1) | CL2007002422A1 (es) |
CO (1) | CO6150139A2 (es) |
CR (1) | CR10638A (es) |
EA (1) | EA017917B1 (es) |
GB (1) | GB0616574D0 (es) |
IL (1) | IL196976A0 (es) |
MA (1) | MA30672B1 (es) |
MX (1) | MX2009001941A (es) |
NO (1) | NO20090834L (es) |
PE (1) | PE20080609A1 (es) |
TW (1) | TW200825074A (es) |
WO (1) | WO2008022994A1 (es) |
ZA (1) | ZA200900886B (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2070922T3 (pl) * | 2004-02-23 | 2012-01-31 | Glaxo Group Ltd | Pochodne azabicyklo[3.1.0]heksanu użyteczne jako modulatory receptorów dopaminowych D3 |
GB0507602D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
GB0507601D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
WO2006133945A1 (en) * | 2005-06-14 | 2006-12-21 | Glaxo Group Limited | Novel compounds |
GB0517191D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
GB0517175D0 (en) | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
US7799815B2 (en) * | 2005-08-22 | 2010-09-21 | Glaxo Group Limited | Triazole derivatives as modulators of dopamine D3 receptors |
GB0517187D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
JP5189076B2 (ja) * | 2006-04-03 | 2013-04-24 | グラクソ グループ リミテッド | ドーパミンd3受容体のモジュレーターとしてのアザビシクロ[3.1.0]ヘキシル誘導体 |
DE602007012531D1 (de) * | 2006-04-03 | 2011-03-31 | Glaxo Group Ltd | Azabicycloä3.1.0ühexanderivate als modulatoren von dopamin-d3-rezeptoren |
US9133159B2 (en) | 2007-06-06 | 2015-09-15 | Neurovance, Inc. | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
US20090069374A1 (en) * | 2007-06-06 | 2009-03-12 | Phil Skolnick | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments |
US11447484B2 (en) | 2018-01-26 | 2022-09-20 | Shionogi & Co., Ltd. | Cyclic compound having dopamine D3 receptor antagonistic effect |
AR127055A1 (es) * | 2021-09-14 | 2023-12-13 | Lilly Co Eli | Sales agonistas de sstr4 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4260941B2 (ja) * | 1998-11-09 | 2009-04-30 | 株式会社片山製薬所 | アゼチジン−3−オール |
AU3147800A (en) * | 1999-03-15 | 2000-10-04 | Novo Nordisk A/S | New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine |
GB0019228D0 (en) * | 2000-08-04 | 2000-09-27 | Smithkline Beecham Plc | Novel pharmaceutical |
PL2070922T3 (pl) * | 2004-02-23 | 2012-01-31 | Glaxo Group Ltd | Pochodne azabicyklo[3.1.0]heksanu użyteczne jako modulatory receptorów dopaminowych D3 |
SE526837C2 (sv) * | 2004-02-24 | 2005-11-08 | Kongsberg Automotive Asa | Växelspakstransmission |
CN1984903A (zh) * | 2004-06-30 | 2007-06-20 | 伊莱利利公司 | 1-(吲哚-6-羰基-d-苯基甘氨酰基)-4-(1-甲基哌啶-4-基)哌嗪d-酒石酸盐 |
GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
-
2006
- 2006-08-21 GB GBGB0616574.0A patent/GB0616574D0/en not_active Ceased
-
2007
- 2007-08-17 PE PE2007001117A patent/PE20080609A1/es not_active Application Discontinuation
- 2007-08-20 CN CN2007800392082A patent/CN101528221B/zh not_active Expired - Fee Related
- 2007-08-20 BR BRPI0716454-8A2A patent/BRPI0716454A2/pt not_active IP Right Cessation
- 2007-08-20 EP EP07788490A patent/EP2054054A1/en not_active Withdrawn
- 2007-08-20 TW TW096130644A patent/TW200825074A/zh unknown
- 2007-08-20 AU AU2007287527A patent/AU2007287527B2/en not_active Ceased
- 2007-08-20 JP JP2009525046A patent/JP5315244B2/ja not_active Expired - Fee Related
- 2007-08-20 KR KR1020097003484A patent/KR101495362B1/ko not_active IP Right Cessation
- 2007-08-20 CL CL200702422A patent/CL2007002422A1/es unknown
- 2007-08-20 MX MX2009001941A patent/MX2009001941A/es active IP Right Grant
- 2007-08-20 WO PCT/EP2007/058636 patent/WO2008022994A1/en active Application Filing
- 2007-08-20 US US11/841,015 patent/US20080058398A1/en not_active Abandoned
- 2007-08-20 CA CA002661437A patent/CA2661437A1/en not_active Abandoned
- 2007-08-20 EA EA200970211A patent/EA017917B1/ru not_active IP Right Cessation
- 2007-08-21 AR ARP070103715A patent/AR062471A1/es not_active Application Discontinuation
-
2009
- 2009-02-06 ZA ZA2009/00886A patent/ZA200900886B/en unknown
- 2009-02-09 IL IL196976A patent/IL196976A0/en unknown
- 2009-02-20 CO CO09017330A patent/CO6150139A2/es unknown
- 2009-02-23 NO NO20090834A patent/NO20090834L/no not_active Application Discontinuation
- 2009-02-25 CR CR10638A patent/CR10638A/es not_active Application Discontinuation
- 2009-02-27 MA MA31673A patent/MA30672B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AR062471A1 (es) | 2008-11-12 |
AU2007287527B2 (en) | 2013-01-31 |
NO20090834L (no) | 2009-03-19 |
JP2010501519A (ja) | 2010-01-21 |
CN101528221B (zh) | 2013-05-08 |
EP2054054A1 (en) | 2009-05-06 |
MX2009001941A (es) | 2009-03-05 |
KR101495362B1 (ko) | 2015-02-24 |
TW200825074A (en) | 2008-06-16 |
JP5315244B2 (ja) | 2013-10-16 |
US20080058398A1 (en) | 2008-03-06 |
BRPI0716454A2 (pt) | 2014-03-04 |
AU2007287527A1 (en) | 2008-02-28 |
CL2007002422A1 (es) | 2008-03-14 |
WO2008022994A1 (en) | 2008-02-28 |
KR20090052327A (ko) | 2009-05-25 |
CR10638A (es) | 2009-03-20 |
EA200970211A1 (ru) | 2009-08-28 |
MA30672B1 (fr) | 2009-08-03 |
CN101528221A (zh) | 2009-09-09 |
IL196976A0 (en) | 2009-11-18 |
GB0616574D0 (en) | 2006-09-27 |
EA017917B1 (ru) | 2013-04-30 |
ZA200900886B (en) | 2011-05-25 |
CA2661437A1 (en) | 2008-02-28 |
PE20080609A1 (es) | 2008-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6150139A2 (es) | Sal de tartrato de 1-[2- fluoruro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3 oxazol-5-il)-4h-1,2,4-triazol-3 il]tio}propil)-3-azabiciclo[3.1.0]-hexano y a sus solvatos, formulaciones farmaceuticas, procedimientos para su preparacion y su | |
RU2378259C2 (ru) | Новые производные аминоиндазолов в качестве лекарственных средств и содержащие их фармацевтические композиции | |
PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
RU2399620C2 (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
ES2536191T3 (es) | Derivados de sulfonamida | |
RU2223116C2 (ru) | Применение производных арил (или гетероарил) азолилкарбинолов в приготовлении лекарственного средства для лечения нарушений, опосредованных избытком вещества p | |
NO20084659L (no) | Ko-krystall av C-glucosidderivat og L-prolin | |
EA201000486A1 (ru) | Ингибитор белка, активирующего 5-липоксигеназу (flap) | |
RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
JP2010513319A5 (es) | ||
GEP20104906B (en) | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors | |
UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
WO2003105771A3 (en) | 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) AZETIDINE-3-CARBOXYLATES AND 1 - ((5-ARYL-1,2,4-OXADIAZOL-3-YL) BENZYL) PYRROLIDINE-3-CARBOXYLATES FOR USE AS EDG RECEPTOR AGONISTS | |
NZ591427A (en) | P38 map kinase inhibitors | |
RU2013107007A (ru) | Бифункциональные соединения, являющиеся ингибиторами rho-киназы, композиция и применение | |
RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
RU2013130222A (ru) | Применение сигма-лигандов от боли при раке костей | |
MX344580B (es) | Combinacion de panobinostat y ruxolitinib en el tratamiento del cancer tal como una neoplasia mieloproliferativa. | |
HRP20080446T3 (en) | Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine | |
HUE029485T2 (en) | New cyclohexylamine derivatives with B2 adrenergic agonist and M3 muscarinic antagonist activity | |
DE602006018713D1 (de) | Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate | |
MX2010004176A (es) | Derivado de triazol 1,3,5-trisustituido. | |
PE20070355A1 (es) | Antagonistas de cgrp seleccionados y procedimientos para su preparacion | |
AR069743A1 (es) | Derivados de pirazol como inhibidores de 5-lipoxigenasa | |
HRP20100265T1 (hr) | Smjesa od pirimidilaminobenzamid spojeva i imatiniba za liječenje ili prevenciju proliferativnih bolesti |